Fentanyl Transdermal System 25 mcg/h transdermal patches
Product details
- Fentanyl Transdermal System 25 mcg/h transdermal patches
Company announcement
Alvogen, Inc. is recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches nationwide.
The recall is due to the potential for patches to be multi-stacked in a single product pouch.
Application of a multi-stacked patch could result in serious, life-threatening, or fatal respiratory depression.
Alvogen has received one serious adverse event related to this recall.
The affected lot is Lot 108319 with an expiration date of April 2027.
The recall was announced on January 31, 2025.
Risk:
There is a possibility that the application of a multi-stacked 25 mcg/h patch could result in serious, life threatening, or fatal respiratory depression. Groups at potential increased risk could include first-time recipients of such patches, children, and the elderly.
Impacted states: Nationwide
Products:
- Fentanyl Transdermal System 25 mcg/h transdermal patches
Contact
For more information, call 866-770-3024 or email alvogensmb@continuumindia.com.
Related recalls
- Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) for Intravenous Infusion
- 0.9% Sodium Chloride Injection, USP, 100 mL
- Compounded Glutathione 200 mg/mL 30 mL multidose vial; Myer’s Cocktail 30 mL multidose vial; Tri-Immune Boost 30 mL multidose vial
- Luna G3 APAP (Model LG3600)
- 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container
- 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container